JP2021523120A5 - - Google Patents
Info
- Publication number
- JP2021523120A5 JP2021523120A5 JP2020561740A JP2020561740A JP2021523120A5 JP 2021523120 A5 JP2021523120 A5 JP 2021523120A5 JP 2020561740 A JP2020561740 A JP 2020561740A JP 2020561740 A JP2020561740 A JP 2020561740A JP 2021523120 A5 JP2021523120 A5 JP 2021523120A5
- Authority
- JP
- Japan
- Prior art keywords
- peaks
- acid
- compound
- salt according
- furthermore
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862667226P | 2018-05-04 | 2018-05-04 | |
| US62/667,226 | 2018-05-04 | ||
| PCT/US2019/030717 WO2019213606A2 (en) | 2018-05-04 | 2019-05-03 | Solid forms of cerdulatinib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523120A JP2021523120A (ja) | 2021-09-02 |
| JP2021523120A5 true JP2021523120A5 (cg-RX-API-DMAC7.html) | 2022-05-12 |
| JP7324778B2 JP7324778B2 (ja) | 2023-08-10 |
Family
ID=66641481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561740A Active JP7324778B2 (ja) | 2018-05-04 | 2019-05-03 | セルデュラチニブ(cerdulatinib)の固体形態 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10865198B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3788035B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7324778B2 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202014412A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019213606A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3383396B1 (en) | 2015-12-04 | 2023-07-12 | Alexion Pharmaceuticals, Inc. | Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma |
| US10851087B2 (en) | 2018-05-04 | 2020-12-01 | Portola Pharmaceuticals, Inc. | Synthesis of cerdulatinib |
| WO2019213606A2 (en) * | 2018-05-04 | 2019-11-07 | Portola Pharmaceuticals, Inc. | Solid forms of cerdulatinib |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60255756A (ja) | 1984-06-01 | 1985-12-17 | Ikeda Mohandou:Kk | アミノアルキルフエノキシ誘導体 |
| WO1995032963A1 (en) | 1994-06-01 | 1995-12-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienylazole compound and thienotriazolodiazepine compound |
| WO2003037352A1 (en) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| ES2373226T3 (es) | 2002-06-28 | 2012-02-01 | Astellas Pharma Inc. | Derivado de diaminopirimidincarboxamida. |
| WO2008009458A1 (en) | 2006-07-21 | 2008-01-24 | Novartis Ag | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| CA2723205C (en) | 2008-04-16 | 2017-03-14 | Portola Pharmaceuticals, Inc. | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| WO2010129802A1 (en) | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
| ES2546294T7 (es) | 2009-05-26 | 2024-06-06 | Abbvie Ireland Unlimited Co | Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias |
| US20120157500A1 (en) | 2009-08-24 | 2012-06-21 | Weikang Tao | Jak inhibition blocks rna interference associated toxicities |
| US20110130415A1 (en) | 2009-12-01 | 2011-06-02 | Rajinder Singh | Protein kinase c inhibitors and uses thereof |
| US9398308B2 (en) | 2010-07-28 | 2016-07-19 | Qualcomm Incorporated | Coding motion prediction direction in video coding |
| WO2012045020A1 (en) * | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine |
| WO2012071336A1 (en) | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Salts and crystalline forms of an apoptosis-inducing agent |
| JP5808818B2 (ja) | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| WO2013023119A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | JAK P13K/mTOR COMBINATION THERAPY |
| HK1206073A1 (en) | 2012-07-24 | 2015-12-31 | 药品循环有限责任公司 | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| WO2014058921A2 (en) | 2012-10-08 | 2014-04-17 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| SG11201503459SA (en) | 2012-11-02 | 2015-06-29 | Pharmacyclics Inc | Tec family kinase inhibitor adjuvant therapy |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016196385A1 (en) | 2015-05-29 | 2016-12-08 | Portola Pharmaceuticals, Inc. | Cerdulatinib for the treatment of b-cell malignancies |
| ES2913119T3 (es) | 2015-08-12 | 2022-05-31 | Portola Pharm Inc | Cerdulatinib para tratar mieloma |
| EP3383396B1 (en) | 2015-12-04 | 2023-07-12 | Alexion Pharmaceuticals, Inc. | Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma |
| US10851087B2 (en) | 2018-05-04 | 2020-12-01 | Portola Pharmaceuticals, Inc. | Synthesis of cerdulatinib |
| WO2019213606A2 (en) * | 2018-05-04 | 2019-11-07 | Portola Pharmaceuticals, Inc. | Solid forms of cerdulatinib |
| KR20210003789A (ko) | 2018-05-04 | 2021-01-12 | 포톨라 파마슈티컬스, 인코포레이티드 | 림프종을 치료하는 방법 |
-
2019
- 2019-05-03 WO PCT/US2019/030717 patent/WO2019213606A2/en not_active Ceased
- 2019-05-03 JP JP2020561740A patent/JP7324778B2/ja active Active
- 2019-05-03 EP EP19726240.5A patent/EP3788035B1/en active Active
- 2019-05-03 US US16/402,684 patent/US10865198B2/en active Active
- 2019-05-03 TW TW108115465A patent/TW202014412A/zh unknown
-
2020
- 2020-11-16 US US17/098,852 patent/US11713309B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7036939B2 (ja) | 癌細胞の成長抑制効果を示す新規なピリミジン誘導体及びそれを含む薬剤学的組成物 | |
| JP7126514B2 (ja) | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス | |
| CN103930399B (zh) | 包含亚氨基亚磺酰基的二取代的5-氟嘧啶衍生物 | |
| TW438781B (en) | Substituted 1,2,3,4-tetrahydronaphthalene derivatives | |
| TWI425945B (zh) | 四氫異喹啉-1-酮衍生物或其鹽 | |
| US20080293711A1 (en) | Chemokine receptor modulators | |
| JP4937760B2 (ja) | 4−(4−メチルピペラジン−1−イルメチル)−n−[4−メチル−3−(4−ピリジン−3−イル)ピリミジン−2−イルアミノ)フェニル]−ベンズアミドの塩形態 | |
| TW201000460A (en) | Amide compound | |
| JP4429724B2 (ja) | [1,2,4]−トリアゾール二環式アデノシンA2aレセプタアンタゴニスト | |
| TW200307539A (en) | Cycloalkyl inhibitors of potassium channel function | |
| WO2008109154A1 (en) | Chemokine receptor modulators | |
| TW200932727A (en) | New acetyl coenzyme a carboxylase (ACC) inhibitors and uses in treatments of obesity and diabetes mellitus | |
| TW200913997A (en) | Heterocyclic compounds | |
| CZ20033508A3 (en) | 5-ht receptor ligands and uses thereof | |
| CN101258131B (zh) | 作为5-HT2c受体激动剂的6-芳烷基氨基-2,3,4,5-四氢-1H-苯并[d]氮杂䓬 | |
| JP2009514782A (ja) | グリコーゲン合成酵素キナーゼ3阻害剤としてのトリアゾロピリミジン誘導体 | |
| EP3822263A1 (en) | Biaryl ether-type quinazoline derivative | |
| TW200815368A (en) | 2-anilino-4-aminoalkyleneaminopyrimidines | |
| EP3107898A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| CN102741226B (zh) | 4-取代的-2-苯氧基-苯胺δ阿片类受体调节剂 | |
| JP2010505961A5 (cg-RX-API-DMAC7.html) | ||
| EP2906554A1 (en) | Solid forms of nilotinib hydrochloride | |
| JP2023078389A (ja) | 重水素化デファクチニブ化合物及びその使用 | |
| HK1232226A1 (zh) | 抑制bet蛋白的具有间位取代的芳族氨基或醚基的3,4-二氢吡啶并[2,3-b]吡嗪酮 | |
| JP6976248B2 (ja) | (r)−1−(4−(6−(2−(4−(3,3−ジフルオロシクロブトキシ)−6−メチルピリジン−2−イル)アセトアミド)ピリダジン−3−イル)−2−フルオロブチル)−n−メチル−1h−1,2,3−トリアゾール−4−カルボキサミドの塩形態および多形体 |